Therapeutics for depression and anxiety disorders

Drug Discovery Today: Therapeutic Strategies

Volumn 1, Issue 1, 2004, Pages 105-109

  Holsboer, Florian ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 CHLORO 1 (2,4 DIMETHOXYLPHENYLSULFONYL) 2,3 DIHYDRO 3 (2 METHOXYPHENYL) 2 OXO 1H INDOL 3 YL] 4 HYDROXY N,N DIMETHYL 2 PYRROLIDINECARBOXAMIDE; 3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; 5 [[2 [1 [3,5 BIS(TRIFLUOROMETHYL)PHENYL]ETHOXY] 3 (4 FLUOROPHENYL) 4 MORPHOLINYL]METHYL] N,N DIMETHYL 1H 1,2,3 TRIAZOLE 4 METHANAMINE; ANTIDEPRESSANT AGENT; ANTISENSE OLIGONUCLEOTIDE; APREPITANT; ATOMOXETINE; C 1073; CORTICOTROPIN RELEASING FACTOR; DULOXETINE; GLUCOCORTICOID; MIFEPRISTONE; MONOAMINE; NKP 608; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TIANEPTINE; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1 RECEPTOR;

ANXIETY DISORDER; ARTICLE; BODY WEIGHT DISORDER; DEPRESSION; DISEASE PREDISPOSITION; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; ENDOCRINE SYSTEM; GENE IDENTIFICATION; GENETIC ANALYSIS; HORMONAL REGULATION; HUMAN; HYPERCORTISOLISM; LIVER TOXICITY; MONOAMINE RELEASE; NAUSEA; NEUROTRANSMISSION; NONHUMAN; RESTLESSNESS; SEXUAL DYSFUNCTION; SIDE EFFECT; STRESS; VISUAL IMPAIRMENT; WEIGHT GAIN; XEROSTOMIA;

EID: 13444271951     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2004.08.012     Document Type: Review

References (31)

1. R. Kessler et al. The epidemiology of major depressive disorder J. Am. Med. Assoc. 289 2003 3095-3105
2. F. Bymaster et al. New approaches to developing antidepressants by enhancing monomainergic neurotransmission Invest. Drugs 12 2003 531-543
3. T. Nickel et al. Clinical and neurobiological effects of tianeptine and paroxetine in major depression J. Clin. Psychopharmacol. 23 2003 155-168
4. M. Nibuya et al. Regulation of BDNF and trkB mRNA in rat brain bay chronic electroconvulsive seizure and antidepressant drug treatments J. Neurosci. 15 1995 7539-7547
5. J. Malberg et al. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus J. Neurosci. 20 2000 9104-9110
6. L. Santarelli et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants Science 301 2003 805-809
7. T. Frodl et al. Hippocampal changes in patients with a first episode of major depression Am. J. Psychiatry 159 2002 1112-1118
8. M.A. Smith et al. Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus J. Neurosci. 15 1995 1768-1777
9. T. Hagerty et al. Identification of a glucocorticoid-responsive element in the promoter region of the mouse tyrosine hydroxylase gene J. Neurochem. 76 2001 825-834
10. S. Wissink et al. Regulation of the rat serotonin-1A receptor gene by corticosteroids J. Biol. Chem. 275 2000 1321-1326
11. F. Holsboer The corticosteroid receptor hypothesis of depression Neuropsychopharmacology 23 2000 477-501
12. H. Reul et al. Chronic treatment of rats with the antidepressant amitryline attenuates the activity of the hypothalamic-pituitray-adrenocortical system Endocrinology 133 1993 312-320
13. J. Belanoff et al. An open label trial of C-1073 (mifepristone) for psychotic major depression Biol. Psychiatry 52 2002 386-392
14. C. Bachmann et al. Effect of chronic administration of selective glucocorticoid receptor antagonists on the rat hypothalamic-pituitary-adrenocortical axis Neuropsychopharmacology 28 2003 1056-1067
15. F. Holsboer The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety J. Psychiatr. Res. 33 1999 181-214
16. I. Heuser et al. Cerebrospinal fluid concentrations of corticotropin-releasing hormone, vasopressin, and somatostatin in depressed patients and healthy controls: Response to amitriptyline treatment Depress. Anxiety 8 1998 71-79
17. P. Timpl et al. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1 Nat. Genet. 19 1998 162-166
18. M. Müller et al. Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress Nat. Neurosci. 6 2003 1100-1107
19. A. Zobel et al. Effects of high-affinity corticotropin-releasing hormone receptor 1 antagonists R121919 in major depression: The first 20 patients treated J. Psychiatr. Res. 34 2000 171-181
20. K. Held et al. Treatment with the CRH1-receptor-antagonists R 121919 improves sleep-EEG in patients with depression J. Psychiatr. Res. 38 2004 129-136
21. H. Künzel et al. Treatment of depression with the CRH-1-receptor antagonist R121919: Endocrine changes and side effects J. Psychiatr. Res. 37 2003 525-533
22. Landgraf R et al. (1999) Release of vasopressin within the brain contributes to neuroendocrine and behavioral regulation. In Progress in Brain Research (Urban I, Burbach J, De Wied eds), Elsevier Science B.V., Amsterdam, pp. 201-220
23. M. Keck et al. Reduction of hypothalamic vasopressinergic hyperdrive contributes to clinically relevant behavioral and neuroendocrine effects of chronic paroxetine treatment in a psychological rat model Neuropsychopharmacology 28 2003 235-243
24. G. Griebel et al. Anxiolytic- and antidressant-like effects of the non-peptide vasopression V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders Proc. Natl. Acad. Sci. USA 99 2002 6370-6375
25. M.S. Kramer et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors Science 281 1998 1640-1645
26. V.A. Spilios D. Nutt Substance P antagonists: Novel agents in the treatment of depression Exp. Opin. Invest. Drugs 9 2000 1871-1875
27. A. Ribeiro-da-Silva T. Hökfelt Neuroanatomical localisation of substance P in the CNS and sensory neurons Neuropeptides 34 2000 256-271
28. J. Landgrebe et al. Molecular characterisation of antidepressant effects in the mouse brain using gene expression profiling J. Psychiatr. Res. 36 2002 119-129
29. E. Marcotte et al. DNA microarrays in neurpsychopharmacology Trends Pharmacol. Sci. 22 2001 426-436
30. R. Cloninger The discovery of susceptibility genes for mental disorders Proc. Natl. Acad. Sci. USA 99 2002 13365-13367
31. D. Baldwin C. Thompson The future of antidepressant pharmacotherapy World Psychiatry 2 2003 3-8